All In Biotech

Drug Trial Radar · NCT07227454

A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

A Double-blind, Randomized, Psychoactive Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine 84 mg in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder in Adolescent Participants With Acute Suicidal Ideation or Behavior

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 258 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

258

Planned (sponsor's estimate)

Start

Jan 8, 2026

Primary completion

Apr 9, 2031

Study completion Sep 15, 2031

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Nov 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate how well JNJ-54135419 works (efficacy) in addition to comprehensive standard of care (SoC) in rapidly reducing the symptoms of major depressive disorder (MDD, a mental disorder characterized by a persistent feeling of sadness and loss of interest in activities) as compared with psychoactive placebo (does not contain JNJ-54135419) plus SoC in adolescent participants with acute suicidal ideation or behavior.

Conditions

  • Depressive Disorder, Major

Interventions

  • EsketamineDrug

    Esketamine will be administered as intranasal solution.

  • MidazolamDrug

    Midazolam will be administered as oral solution.

  • Oral PlaceboOther

    Placebo will be administered as oral solution.

  • Intranasal PlaceboOther

    Intranasal placebo will be administered as nasal solution.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Depressive Symptoms Measured by Children's Depression Rating Scale - Revised (CDRS-R) Total Score at 24 Hours Post First DoseTime frame: Baseline (pre-dose on Day 1) and 24 hours post first dose (i.e., Day 2)

Locations

49 sites in 7 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • Yale Child Study Center

    New Haven, Connecticut · Recruiting

  • Children's National Medical Center

    Washington D.C., District of Columbia · Recruiting

  • Peachford Hospital-Atlanta Behavioral Research

    Atlanta, Georgia · Recruiting

  • Endeavor Health Evanston Hospital

    Evanston, Illinois · Recruiting

  • Johns Hopkins University

    Baltimore, Maryland · Recruiting

  • Boston Childrens Hospital

    Boston, Massachusetts · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina · Recruiting

  • University of Cincinnati

    Cincinnati, Ohio · Recruiting

  • Bradley Hospital

    East Providence, Rhode Island · Recruiting

  • John S Dunn Behavioral Sciences Center at UTHealth Houston

    Houston, Texas · Recruiting

  • Sociedade Literaria e Caritativa Santo Agostinho Hospital Sao Jose

    Criciúma, Brazil · Recruiting

  • Universidade Federal do Rio Grande do Norte Hospital Universitario Onofre Lopes

    Natal, Brazil · Recruiting

  • Instituto Apice

    Salvador, Brazil · Recruiting

  • Centro Integrado Facili

    São Bernardo do Campo, Brazil · Recruiting

  • Instituto de Pesquisa Pensi Sandra Mutarelli Setubal

    São Paulo, Brazil · Recruiting

  • Hospital Das Clinicas Da Faculdade De Medicina Da USP

    São Paulo, Brazil · Recruiting

  • Vadaskert Gyermek es Ifjusagpszichiatriai Korhaz es Szakambulancia

    Budapest, Hungary · Recruiting

  • Debreceni Egyetem Klinikai Kozpont

    Debrecen, Hungary · Recruiting

  • Petz Aladar Megyei Oktato Korhaz

    Győr, Hungary · Recruiting

  • Szegedi Tudomanyegyetem

    Szeged, Hungary · Recruiting

  • Presidio Ospedaliero Santa Marta e Santa Venera

    Acireale, Italy · Recruiting

  • Azienda Ospedaliera G. Brotzu

    Cagliari, Italy · Recruiting

  • AOU Meyer

    Florence, Italy · Recruiting

  • Azienda Ospedaliera Universitaria Policlinico Riuniti di Foggia

    Foggia, Italy · Recruiting

  • G.Gaslini Institute

    Genova, Italy · Recruiting

  • Ospedale di Merano

    Merano, Italy · Recruiting

  • Azienda Ospedaliera Universitaria Federico II

    Naples, Italy · Recruiting

  • Azienda Ospedaliero Universitaria di Sassari

    Sassari, Italy · Recruiting

  • Spitalul Clinic de Psihiatrie Prof Dr Alexandru Obregia

    Bucharest, Romania · Recruiting

  • Spitalul Clinic de Urgenta pentru Copii Cluj Napoca

    Cluj-Napoca, Romania · Recruiting

  • Spitalul Clinic De Psihiatrie Doctor Gheorghe Preda

    Sibiu, Romania · Recruiting

  • Spitalul Clinic de Urgenta pentru Copii 'Louis Turcanu' Timisoara

    Timișoara, Romania · Recruiting

  • Hosp Univ Vall D Hebron

    Barcelona, Spain · Recruiting

  • Hosp. Clinic de Barcelona

    Barcelona, Spain · Recruiting

  • Hosp. Sant Joan de Deu

    Esplugues de Llobregat, Spain · Recruiting

  • Hosp. Gral. Univ. Gregorio Maranon

    Madrid, Spain · Recruiting

  • Hosp. Univ. La Paz

    Madrid, Spain · Recruiting

  • Fundacio Althaia Xarxa Assistencial Universitaria de Manresa

    Manresa, Spain · Recruiting

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.